Experimental Therapeutics for the Treatment of Triple Negative Breast Cancer
作者： Julian Dzeyk , Babasaheb Yadav , Rhonda J.
DOI: 10.5772/23054
关键词: Gene isoform 、 Gene expression profiling 、 Estrogen receptor 、 Internal medicine 、 Triple-negative breast cancer 、 Oncology 、 Poorly differentiated 、 Immunohistochemistry 、 Epidermal growth factor receptor 、 Progesterone receptor 、 Medicine
摘要: Triple negative breast cancers (TNBCs) are defined as tumors that do not express the estrogen receptor (ER), progesterone (PR) and HER2 isoform of epidermal growth factor (EGFR)(Foulkes et al., 2010). They account for approximately 10-17% all (Reis-Filho & Tutt, 2008). Clinically, they more prevalent among young African African-American women TNBCs poorly differentiated, highly malignant, aggressive have a poor outcome (Chen Russo, 2009). also characterized by early recurrence high rate visceral metastasis (Conte Guarneri, Moreover, peak risk occurs within three years diagnosis mortality rates increased five after (Kwan The molecular changes associated with been various immunohistochemistry gene expression profiling studies. Specifically, include p53 mutation, overexpression Ki67 EGFR, dysfunction in BRCA1 pathway (Rowe It is estimated EGFR expressed 60% (Arslan In addition, an over cytokeratins 5, 6, 14, 17, smooth muscle actin, P-cadherin c-kit (Irvin Carey, 2008, Venkitaraman,
intechopen.com
intechweb.org 参考文章(97)
Andrzej S. Tarnawski, Eric C. Chu, PTEN regulatory functions in tumor suppression and cell biology. Medical Science Monitor. ,vol. 10, ,(2004)
Cara A. Mosley, Dennis C. Liotta, James P. Snyder, Highly active anticancer curcumin analogues. Advances in Experimental Medicine and Biology. ,vol. 595, pp. 77- 103 ,(2007) , 10.1007/978-0-387-46401-5_2
Bentham Science Publisher Bentham Science Publisher, Telomerase inhibition in cancer therapeutics: molecular-based approaches. Current Medicinal Chemistry. ,vol. 13, pp. 2875- 2888 ,(2006) , 10.2174/092986706778521887
Alok C. Bharti, Bharat B. Aggarwal, Anushree Kumar, Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Research. ,vol. 23, pp. 363- 398 ,(2003)
Danica L. Rowe, Tuba Ozbay, Ruth M. O'Regan, Rita Nahta, Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin Breast Cancer: Basic and Clinical Research. ,vol. 3, pp. 61- 75 ,(2009) , 10.4137/BCBCR.S3067
JS Reis‐Filho, ANJ Tutt, None, Triple negative tumours : a critical review Histopathology. ,vol. 52, pp. 108- 118 ,(2007) , 10.1111/J.1365-2559.2007.02889.X
Emma C. Stuart, Rhonda J. Rosengren, The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells Life Sciences. ,vol. 82, pp. 943- 948 ,(2008) , 10.1016/J.LFS.2008.02.009
J. M. Adams, The Bcl-2 Protein Family: Arbiters of Cell Survival Science. ,vol. 281, pp. 1322- 1326 ,(1998) , 10.1126/SCIENCE.281.5381.1322
Shala L. Thomas, Diansheng Zhong, Wei Zhou, Sanna Malik, Dennis Liotta, James P. Snyder, Ernest Hamel, Paraskevi Giannakakou, EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle. ,vol. 7, pp. 2409- 2417 ,(2008) , 10.4161/CC.6410
D. K. Biswas, S.-C. Dai, A. Cruz, B. Weiser, E. Graner, A. B. Pardee, The nuclear factor kappa B (NF-κB): A potential therapeutic target for estrogen receptor negative breast cancers Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 10386- 10391 ,(2001) , 10.1073/PNAS.151257998